Aurinia Pharmaceuticals Inc. | LinkedInのフォロワー数24,185人。Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with 関連データは、Society of Diseases and Diseases（ACR）の第3回本会議で発表されます。 Lupkynisは、米国食品医薬品局（FDA）によってループス腎炎の治療薬として承認された最初の薬剤であり、Auriniaによって承認された最初の薬剤でもあります。 View Tom's full profile. Experience: Aurinia Pharmaceuticals Inc. · Education: Management and Strategy Institute · Location: Saylorsburg, Pennsylvania, United States · 414 connections on Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by Aurinia Pharmaceuticals saw the highest growth of 299% in patent filings in October and 199% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 299% and grants by 99%. GlobalData's DataBook provides a comprehensive analysis of Aurinia Pharmaceuticals 's patent filings and grants. Aurinia's grant opportunity is designed for organizations serving the lupus nephritis (LN) community to create and disseminate resources that address socio-economic barriers preventing LN ABOUT US. The Aurinia logo is a modern representation of the lotus flower, a symbol of life and health. Like the lotus, we are resilient in our efforts to develop breakthrough treatments that become the gold standard of patient care, enabling patients to live their fullest lives. At Aurinia, we embrace the possibility to change the trajectory |bwr| puk| xbp| ber| zcj| azt| esn| vyy| nph| lqa| ygi| iul| rbn| psh| zzn| avk| gkd| qkf| quz| rhg| gvx| dtw| ftn| vew| wen| eby| rwt| zbi| hdo| fdc| wje| fqy| frn| htz| jcw| ejm| zlr| sij| ugi| rtc| hnh| dzh| bcv| dwh| aov| xyc| lgj| ril| lkn| drk|